Serving hundreds of leading biopharmaceutical companies globally:

Generated: February 21, 2019

DrugPatentWatch Database Preview

AVASTIN Drug Profile

« Back to Dashboard

Summary for Tradename: AVASTIN

Patents:	714
Applicants:	1
BLAs:	1
Suppliers: see list	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AVASTIN

Pharmacology for AVASTIN

Mechanism of Action	Vascular Endothelial Growth Factor Receptor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions

US Patents for AVASTIN

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Patent Expiration	Status	Orphan	Source
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26	➤ Sign Up	IMMATICS BIOTECHNOLOGY GMBH (Tuebingen, DE)	➤ Sign Up	RX		search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26	➤ Sign Up	SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR)	➤ Sign Up	RX		search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26	➤ Sign Up	IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)	➤ Sign Up	RX		search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26	➤ Sign Up		➤ Sign Up	RX		search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26	➤ Sign Up	TARIS Biomedical LLC (Lexington, MA)	➤ Sign Up	RX		search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26	➤ Sign Up		➤ Sign Up	RX		search
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Patent Expiration	Status	Orphan	Source

International Patents for AVASTIN

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
Japan	5992325	➤ Sign Up
Argentina	098647	➤ Sign Up
Australia	2016226264	➤ Sign Up
Poland	313907	➤ Sign Up
World Intellectual Property Organization (WIPO)	2006124413	➤ Sign Up
Japan	2014503535	➤ Sign Up
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for AVASTIN

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2014C/037	Belgium	➤ Sign Up	PRODUCT NAME: PACLITAXEL DANS UNE FORMULATION DE NANOPARTICULE LIEES A L'ALBUMINE; AUTHORISATION NUMBER AND DATE: EU/1/07/428 20131230
2006/025	Ireland	➤ Sign Up	PRODUCT NAME: NATALIZUMAB (ALSO KNOWN AS TYSABRI); REGISTRATION NO/DATE: EU/1/06/346/001 20060627
92780	Luxembourg	➤ Sign Up	PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
122015000061	Germany	➤ Sign Up	PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
300673	Netherlands	➤ Sign Up	PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
23/2006	Austria	➤ Sign Up	PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey

Merck

Accenture

Baxter

Queensland Health

Chubb

Julphar

Daiichi Sankyo

US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.